Natera: Q1 Earnings Insights

Shares of Natera NTRA rose in after-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share fell 64.44% over the past year to ($0.74), which beat the estimate of ($1.02).

Revenue of $152,316,000 rose by 62.02% from the same period last year, which beat the estimate of $114,370,000.

Outlook

Natera Sees FY21 Revs $550M-$575M Vs $514.68M Est; Sees 2021 Gross Margin ~52%-55% Of Revenues

Details Of The Call

Date: May 06, 2021

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/29k86t7p

Technicals

52-week high: $127.19

52-week low: $35.51

Price action over last quarter: down 10.63%

Company Overview

Natera Inc is operative in the healthcare field in the United States. Its core business is to offer invasive and other means of diagnosing the genetic features of a fetus. Natera's array of diagnostic services include Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by studying the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother's blood and a blood sample from the alleged father. The Company acquires its revenue by billing an insurance carrier, a clinic, or a patient for the test upon delivery of the test result.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!